Prospective evaluation of pharmacokinetically guided dosing of carboplatin in Japanese patients with cancer

Tomoya Shimokata, Yuichi Ando, Yoshinari Yasuda, Akinobu Hamada, Kenji Kawada, Hideyuki Saito, Seiichi Matsuo, Masashi Kondo, Kazuyoshi Imaizumi, Yoshinori Hasegawa

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The Calvert formula, that is, carboplatin dose (mg) = target area under the concentration versus time curve (AUC) × (glomerular filtration rate [GFR] + 25), has not been validated in Japanese subjects in whom the GFR was accurately measured. The purpose of this study is to evaluate the validity of this formula for Japanese patients with cancer and modify it for this population. The GFR was measured on the basis of inulin clearance, which is considered to reflect the accurate GFR. Inulin clearance was measured in 28 patients with cancer. The adjusted 24-h creatinine clearance (24-h Ccr) was unbiased (mean prediction error [MPE] ± SE = -2.3 ± 4.5%) and acceptably precise (root mean squared error = 23.7%) for GFR assessment. The pharmacokinetics of carboplatin were analyzed in 21 patients with a GFR of 17.2-91.4 mL/min. The original Calvert formula overestimated carboplatin clearance, resulting in an MPE of 14.3%. When we revised the Calvert formula for Japanese patients by substituting a non-renal clearance of 15 for 25, that is, dose = target AUC × (GFR + 15), the MPE decreased to -0.1% (P < 0.001). We conclude that the adjusted 24-h Ccr is acceptably precise for GFR assessment, and the non-renal clearance of carboplatin is suggested to be lower in Japanese patients with cancer than in their Western counterparts. (Cancer Sci 2010; 101: 2601-2605)

Original languageEnglish
Pages (from-to)2601-2605
Number of pages5
JournalCancer science
Volume101
Issue number12
DOIs
Publication statusPublished - 01-12-2010
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Prospective evaluation of pharmacokinetically guided dosing of carboplatin in Japanese patients with cancer'. Together they form a unique fingerprint.

  • Cite this